1 ratings / 5 average


Yuasa T, Urakami S, Yamamoto S et al.

Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan.

 Urology 2011;77:831–5.

Editor’s note: Several targeted agents are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). These agents target principally the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin. The agents display greater antitumor activity than older treatments, with response rates ranging from 10% in patients treated with sorafenib (N Engl J Med 2007;356:125–34) to 47% in those treated with sunitinib (J Clin Oncol 2009;27:3584–90), and increased progression-free survival rates when used as either first- or second-line treatment. Despite this activity, biomarkers are not currently used in clinical practice to predict tumor response to these agents.

Return to top